At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Placebo 152a +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-dose, Randomised, Double-blind, Controlled, 2-way Cross-over Study to Assess the Potential for Bronchoconstriction of the New Propellant HFA-152a Versus the Marketed HFA-134a Propellant, in Adult Subjects With Mild Asthma
In Brief
A Phase 2 clinical trial evaluating Placebo 152a and Placebo 134a for Asthma. Completed, enrolled 25 participants across 1 site.
Detailed Summary
This is a Phase IIa, multicentre, single dose, randomised, double blind, controlled, 2 way cross-over study to evaluate the potential for bronchoconstriction of the new HFA-152a propellant (single dose) versus the marketed HFA-134a propellant (single dose) in adults with mild asthma. HFA=Hydrofluoroalkane
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedJul 2022
Enrollment StartAug 2022
Primary CompletionOct 2022
TodayJul 2026
First PostedJul 25, 2022
Enrollment StartAug 3, 2022
Primary CompletionOct 31, 2022
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 3.9 years ago
Interventions
Placebo 152adrug
Placebo pressurised metered-dose inhaler (pMDI) formulated with the 152a propellant
Placebo 134adrug
Placebo pressurised metered-dose inhaler (pMDI) formulated with the 134a propellant